Advanced search
Publication Cover
Journal of Medical Economics Volume 21, 2018 - Issue 7
Submit an article Journal homepage
6,043
Views
25
CrossRef citations to date
0
Altmetric
Neurology

Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England

Robert HettleParexel Access Consulting, Parexel International, Uxbridge, UK;
,
Gerard HartyMERCK, Feltham, UK; Correspondence[email protected]
&
Schiffon L. WongEMD Serono Inc, Billerica, MA, USA
Pages 676-686 | Received 06 Feb 2018, Accepted 27 Mar 2018, Published online: 16 Apr 2018

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.